Predicting Competitive Effects from Prescription Drug Mergers: How Standard Economic Analysis Can Go Wrong.
- Published in:
- Antitrust Bulletin, 2014, v. 59, n. 3, p. 593, doi. 10.1177/0003603X1405900309
- By:
- Publication type:
- Article
Works matching DE "COMPETITION in the drug industry"
Results: 28
1
2
Nonprice Competition in “Substitute” Drugs: The FTC's Blind Spot.
- Published in:
- Antitrust Bulletin, 2014, v. 59, n. 3, p. 579, doi. 10.1177/0003603X1405900308
- By:
- Publication type:
- Article
3
FTC v. Lundbeck: Is Anything in Antitrust Obvious, Like, Ever?
- Published in:
- Antitrust Bulletin, 2014, v. 59, n. 3, p. 557, doi. 10.1177/0003603X1405900307
- By:
- Publication type:
- Article
4
When the Price Isn't Right—Lundbeck and a Path to Analyze Competition in Drug Research and Development.
- Published in:
- Antitrust Bulletin, 2014, v. 59, n. 3, p. 527, doi. 10.1177/0003603X1405900306
- By:
- Publication type:
- Article
5
Govt. should concentrate on Quality Control of drugs rather than price control.
- Published in:
- 2014
- By:
- Publication type:
- Proceeding
6
Pfizer to collaborate with Mylan to develop and market Generics in Japan.
- Published in:
- Pulse International, 2012, v. 13, n. 18, p. 8
- Publication type:
- Article
7
EXCESSIVE DRUG PRICING AS AN ANTITRUST VIOLATION.
- Published in:
- Antitrust Law Journal, 2019, v. 82, n. 2, p. 701
- By:
- Publication type:
- Article
8
ACCOUNTING FOR COMPLEMENTARITIES IN HOSPITAL MERGERS: IS A SUBSTITUTE NEEDED FOR CURRENT APPROACHES?
- Published in:
- Antitrust Law Journal, 2019, v. 82, n. 2, p. 497
- By:
- Publication type:
- Article
9
UP OR DOWN? THE PRICE EFFECTS OF MERGERS OF INTERMEDIARIES.
- Published in:
- Antitrust Law Journal, 2019, v. 82, n. 2, p. 643
- By:
- Publication type:
- Article
10
PHARMACEUTICAL PRODUCT HOPPING: IS THERE A ROLE FOR ANTITRUST SCRUTINY?
- Published in:
- Antitrust Law Journal, 2019, v. 82, n. 2, p. 679
- By:
- Publication type:
- Article
11
PHARMACEUTICAL PRODUCT HOPPING: IS THERE A ROLE FOR ANTITRUST SCRUTINY?
- Published in:
- Antitrust Law Journal, 2018, v. 82, n. 2, p. 679
- By:
- Publication type:
- Article
12
Getting Smart in How We Pay for HCV Drugs: KAOS vs CONTROL.
- Published in:
- Clinical Infectious Diseases, 2015, v. 61, n. 2, p. 169, doi. 10.1093/cid/civ221
- By:
- Publication type:
- Article
13
Pharma ball gazing.
- Published in:
- Chemistry & Industry, 2015, v. 79, n. 8, p. 40, doi. 10.1002/cind.798_14.x
- Publication type:
- Article
14
Generic race to market.
- Published in:
- Chemistry & Industry, 2015, v. 79, n. 4, p. 47, doi. 10.1002/cind.794_16.x
- Publication type:
- Article
15
Preferred supplier contracts in post-patent prescription drug markets.
- Published in:
- 2017
- By:
- Publication type:
- journal article
16
Big Pharma's Anticompetitive Practices Delaying Generic Entry: Has the Tide Turned?
- Published in:
- Journal of European Competition Law & Practice, 2014, v. 5, n. 7, p. 421, doi. 10.1093/jeclap/lpu079
- By:
- Publication type:
- Article
17
Denigrating Competitors: To What Extent is it Permissible under Article 102 TFEU (France)?
- Published in:
- Journal of European Competition Law & Practice, 2014, v. 5, n. 1, p. 39, doi. 10.1093/jeclap/lpt064
- By:
- Publication type:
- Article
18
Addressing the Lack of Competition in Generic Drugs to Improve Healthcare Quality and Safety.
- Published in:
- 2018
- By:
- Publication type:
- journal article
19
ENTRY THREATS AND PRICING IN THE GENERIC DRUG INDUSTRY.
- Published in:
- Review of Economics & Statistics, 2014, v. 96, n. 2, p. 214, doi. 10.1162/REST_a_00382
- By:
- Publication type:
- Article
20
A dose of competition: EU antitrust law in the pharmaceuticals sector.
- Published in:
- Journal of Antitrust Enforcement, 2016, v. 4, n. 2, p. 381, doi. 10.1093/jaenfo/jnw001
- By:
- Publication type:
- Article
21
2018 STUART ROME LECTURE: ORIGINS OF AND POTENTIAL SOLUTIONS TO HIGH PRESCRIPTION DRUG PRICES IN THE U.S.
- Published in:
- Journal of Health Care Law & Policy, 2019, v. 22, n. 2, p. 1
- By:
- Publication type:
- Article
22
Competition and Intellectual Property Policies in the Indian Pharmaceutical Sector.
- Published in:
- Vikalpa: The Journal for Decision Makers, 2017, v. 42, n. 2, p. 61, doi. 10.1177/0256090917704561
- By:
- Publication type:
- Article
23
Merger mania: mergers and acquisitions in the generic drug sector from 1995 to 2016.
- Published in:
- 2017
- By:
- Publication type:
- journal article
24
High Generic Drug Prices and Market Competition: A Retrospective Cohort Study.
- Published in:
- 2017
- By:
- Publication type:
- journal article
25
"PAY FOR DELAY": LEGITIMATE CONDUCT TO DEFEND VALID PATENT RIGHTS OR ANTICOMPETITIVE BEHAVIOUR?
- Published in:
- Victoria University of Wellington Law Review, 2018, v. 49, n. 1, p. 25
- By:
- Publication type:
- Article
26
Building a better government affairs function in China.
- Published in:
- China Business Review, 2016, p. 1
- By:
- Publication type:
- Article
27
Paradox of wages/GP.
- Published in:
- 2014
- By:
- Publication type:
- Opinion
28
HATCH-WAXMAN PATENT LITIGATION AND INTER PARTES REVIEW: A NEW SORT OF COMPETITION.
- Published in:
- Alabama Law Review, 2017, v. 69, n. 1, p. 59
- By:
- Publication type:
- Article